Picato (ingenol mebutate)
Picato (Ingenol mebutate) gel is a new drug designed for local treatment of non-hyperkeratotic, non-hypertrophic, actinic keratosis in adults.
Treatment is not directly compared to relevant alternatives, but a Cochrane review concludes that the effect is comparable to diclofenac (Solaraze) and imiquimod (Aldara).
The price of Picato gel is comparable to Solaraze gel, but is considerably more expensive than Aldara creme, which economically favors Aldara as first choice. However, the short period of treatment necessary with Picato (2 or 3 days) compared to weeks to months of treatment with Aldara and Solaraze favors Picato. At the moment none of the drugs are subject to reimbursement.
The treatment method should always be based on consultations with a dermatologist. The condition is not healed even though lesions may disappear initially after treatment with Picato. Continuous control of the skin is necessary.
Picato was marketed January 7th 2013.